"label","rationale","description","uuid:ID","id","name","instanceType"
"","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","The main design for the study","4e94b0ef-9539-4993-a9f8-24e05098b3a6","StudyDesign_1","Study Design 1","StudyDesign"
